Home Featured Page 269

Featured

Latest

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

Psychedelic Research Bulletin: March 2021

atai Life Sciences acquires majority stake in Psyber, Inc., to develop...

Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic...

Music is a ‘Hidden Therapist’ in Psilocybin Therapy

Working with Internal Family Systems (IFS) Therapy and Psychedelics: Everything You...

Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND...

Lobe Sciences Appoints Ilan Hayman to Advisory Board

Entheon Biomedical Corp. Launches HaluGen’s Psychedelics Genetic Test

Tryp Therapeutics Announces Listing on OTCQB and DTC Eligibility

PT238 – Kile Ortigo – Integration and Existential Exploration

1...268269270...304 Page 269 of 304

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

Psychedelic Research Bulletin: March 2021

atai Life Sciences acquires majority stake in Psyber, Inc., to develop...

Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic...

Music is a ‘Hidden Therapist’ in Psilocybin Therapy

Working with Internal Family Systems (IFS) Therapy and Psychedelics: Everything You...

Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND...

Lobe Sciences Appoints Ilan Hayman to Advisory Board

Entheon Biomedical Corp. Launches HaluGen’s Psychedelics Genetic Test

Tryp Therapeutics Announces Listing on OTCQB and DTC Eligibility

PT238 – Kile Ortigo – Integration and Existential Exploration

EDITOR PICKS

The Psychedelic News Feed: December 8 – 14, 2025

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY